Further data against the use of cyproterone acetate in gender affirming hormone therapy regimens

J Clin Endocrinol Metab. 2024 Oct 16:dgae739. doi: 10.1210/clinem/dgae739. Online ahead of print.

Authors

Daniel J Slack^{1

2}, Joshua D Safer^{1

2}

Affiliations

¹ Mount Sinai Center for Transgender Medicine and Surgery, New York, NY, USA.
² Division of Endocrinology, Mount Sinai Health System and Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 39412226
DOI: 10.1210/clinem/dgae739

No abstract available

Keywords: Breast development; Cyproterone acetate; Gender affirming hormone therapy; Spironolactone; Transfeminine; Transgender.